Pharmaceutics 2020 Mar 5; 12: 233. doi: 10.3390.11) Louis D, Perry A, Reifenberger G et al: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuro-pathol 2016; DOI 10.1007/s00401-016-1545-1.12) Lee J, Park SH, Kim YZ: Prognostic Evaluation of Neurological Assessment of the Neuro-Oncology Scale in Glioblastoma Patients. Brain Tumor Res Treat. 2018; 6: 22-30.13) Brennan CW, Verhaak RG, McKenna A et al: The somatic genomic landscape of glioblastoma Cell. 2013 Oct 10; 155: 462-477.14) Matsutani M: Brain tumor therapeutics, KINPODO, 5522016.15) Fukuda H, Kawano T: The Role of C-CAT (Center for Cancer Genomics and Advanced Therapeutics) for Cancer Genomic Medicine in Japan Iryou. 2020; 74: 120-126.16) Zehir A, Benayed R, Shah RH et al: Mutational land-scape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nat Med. 2017; 23: 703-713.17) Lapointe S, Perry A, Butowski NA: Primary brain tumours in adults. Lancet. 2018; 4: 432-446.18) Zhao G, Xie L, Guo W et al: Journal Clinc Oncology. 2020; 38: suppl.e23528.
元のページ ../index.html#44